Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
The pleiotropic effects of PCSK9 in cardiovascular diseases beyond cholesterol metabolism.
Acta Physiol (Oxf)
February 2025
Henan Key Laboratory of Medical Tissue Regeneration, Xinxiang Medical University, Xinxiang, China.
Cardiovascular diseases (CVD) are the leading cause of morbidity and mortality globally, with elevated low-density lipoprotein cholesterol (LDL-C) levels being a major risk factor. Proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a critical role in regulating LDL-C levels by promoting the degradation of hepatic low-density lipoprotein receptors (LDLR) responsible for clearing LDL-C from the circulation. PCSK9 inhibitors are novel lipid-modifying agents that have demonstrated remarkable efficacy in reducing plasma LDL-C levels and decreasing the incidence of CVD.
View Article and Find Full Text PDFNatural Products From Plants Targeting Leptin Resistance for the Future Development of Anti-Obesity Agents.
Phytother Res
January 2025
Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Obesity is a serious health threat, which has affected 16% of adults globally in 2022 and shows a trend toward youthfulness. Leptin, as a regulator of body weight, can suppress appetite and promote energy expenditure, making it potential in obesity treatment. Nevertheless, with the progress of relevant research, it is worth noting that monotherapy with leptin is not an effective strategy since most obese individuals are hyperleptinemic and resistant to leptin, where high levels of leptin fail to exert its weight-loss effects.
View Article and Find Full Text PDFROS Regulation in CNS Disorder Therapy: Unveiling the Dual Roles of Nanomedicine.
Small
December 2024
School of Life Science, Beijing Institute of Technology, Beijing, 100081, P. R. China.
The treatment of brain diseases has always been the focus of attention. Due to the presence of the blood-brain barrier (BBB), most small molecule drugs are difficult to reach the brain, leading to undesirable therapeutic outcomes. Recently, nanomedicines that can cross the BBB and precisely target lesion sites have emerged as thrilling tools to enhance the early diagnosis and treat various intractable brain disorders.
View Article and Find Full Text PDFUnderstanding general practice funding models in Australia and beyond.
Aust J Gen Pract
December 2024
MBBS, MSC, PhD, FRACGP, Chief Medical Officer, Avant Mutual Group Limited, Sydney, NSW; Research Fellow, Centre for Health Economics Research and Evaluation, University of Technology Sydney, Sydney, NSW; AJGP Editorial Advisory Committee member, RACGP, Melbourne, Vic.
Article Synopsis
- Australia is undergoing funding reform for general practice, including updates to Medicare and the MyMedicare voluntary registration.
- The article aims to explain health economic concepts related to these reforms, detailing various funding models and their pros and cons.
- Common funding models like fee-for-service and capitation are discussed, highlighting the need for effective blended models to ensure quality care while sustaining provider payments in the future.
Blinatumomab for the treatment of acute lymphoblastic leukemia in a real-world setting: clinical vignettes.
Leuk Lymphoma
November 2024
Department of Leukemia, M.D. Anderson Cancer Center, The University of Texas, Houston, TX, USA.
Blinatumomab, a CD19/CD3 bispecific T-cell engager; inotuzumab ozogamicin (INO), a CD22 antibody drug conjugate; and chimeric-antigen receptor (CAR) T-cell constructs are novel immune-therapeutic options for treatment of acute lymphoblastic leukemia (ALL). The use of blinatumomab has recently expanded to multiple B-ALL treatment settings. Despite the efficacy of blinatumomab, its use can be challenging in the real-world because of limited experience with its administration and management of toxicities.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!